Metronomic S-1 Chemotherapy and Vandetanib: An Efficacious and Nontoxic Treatment for Hepatocellular Carcinoma
Background: Metronomic chemotherapy involves frequent, regular administration of cytotoxic drugs at nontoxic doses, usually without prolonged breaks. We investigated the therapeutic efficacies of metronomic S-1, an oral 5-fluorouracil prodrug, and vandetanib, an epidermal growth factor receptor and...
Main Authors: | Hideki Iwamoto, Takuji Torimura, Toru Nakamura, Osamu Hashimoto, Kinya Inoue, Junichi Kurogi, Takashi Niizeki, Reiichiro Kuwahara, Mitsuhiko Abe, Hiromori Koga, Hirohisa Yano, Robert S. Kerbel, Takato Ueno, Michio Sata |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2011-03-01
|
Series: | Neoplasia: An International Journal for Oncology Research |
Online Access: | http://www.sciencedirect.com/science/article/pii/S1476558611800679 |
Similar Items
-
Efficacy and tolerability of Sorafenib plus metronomic chemotherapy S-1 for advanced hepatocellular carcinoma in preclinical and clinical assessments
by: Hiroyuki Suzuki, et al.
Published: (2021-11-01) -
Antiangiogenic and Antitumor Activities of Aflibercept, a Soluble VEGF Receptor-1 and -2, in a Mouse Model of Hepatocellular Carcinoma
by: Takuji Torimura, et al.
Published: (2016-07-01) -
Cell cycle regulation by the Wee1 Inhibitor PD0166285, Pyrido [2,3-d] pyimidine, in the B16 mouse melanoma cell line
by: Sakamoto Masaharu, et al.
Published: (2006-12-01) -
Apoferritin/Vandetanib Association Is Long-Term Stable but Does Not Improve Pharmacological Properties of Vandetanib
by: Kateřina Jáklová, et al.
Published: (2021-04-01) -
Radiosensitisation of Hepatocellular Carcinoma Cells by Vandetanib
by: Sami Znati, et al.
Published: (2020-07-01)